I agree that this site is using cookies. You can find further informations here.
X
Mesa, Ruben
409  results:
OpenAccess-fulltext X
Search for persons X
?
1

Targeting lysine demethylase 6B ameliorates ASXL1 truncatio..:

Ge, Guo ; Zhang, Peng ; Sui, Pinpin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10760961/.  , 2024
Link: http://www.ncbi.nlm.nih...
 
?
2

Symptomatic benefit of momelotinib in patients with myelofi..:

Mesa, Ruben A ; Hudgens, Stacie ; Floden, Lysbeth...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225216/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Safety and efficacy of zinpentraxin alfa as monotherapy or ..:

Verstovsek, Srdan ; Foltz, Lynda ; Gupta, Vikas...
https://vbn.aau.dk/da/publications/965feb45-9b9b-47b0-b264-8b4ca378ee3b.  , 2023
Link: https://vbn.aau.dk/da/pu..
 
?
4

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDR..:

Palandri, Francesca ; Masarova, Lucia ; Verstovsek, Srdan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431522/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
5

Pacritinib is a potent ACVR1 inhibitor with significant ane..:

Oh, Stephen T ; Mesa, Ruben A ; Harrison, Claire N...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561048/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Long-Term Hematologic Improvement in a Patient With Cytopen..:

Yacoub, Abdulraheem ; Mesa, Ruben A ; Oh, Stephen T
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929105/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SA..:

Kremyanskaya, Marina ; Harrison, Claire ; Bose, Prithviraj...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431317/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

IMPROVING DIVERSE PARTICIPATION IN CANCER CLINICAL TRIALS:

Mesa, Ruben ; Jones, Rebecca T
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552009/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCO..:

Al-Ali, Haifa Kathrin ; Mesa, Ruben ; Hamer-Maansson, J.E..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429189/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
10

IMPROVING DIVERSE PARTICIPATION IN CANCER CLINICAL TRIALS:

Mesa, Ruben ; Jones, Rebecca T
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493734/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
11

Symptomatic benefit of momelotinib in patients with myelofi..:

mesa, ruben ; Hudgens, Stacie ; Floden, Lysbeth...
Cancer Medicine;12(9).  , 2023
Link: https://hdl.handle.net/1..
 
?
12

Ten years of treatment with ruxolitinib for myelofibrosis: ..:

Verstovsek, Srdan ; Mesa, Ruben A ; Livingston, Robert A..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373260/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
13

Ruxolitinib Versus Best Available Therapy for Polycythemia ..:

Harrison, Claire N ; Nangalia, Jyoti ; Boucher, Rebecca...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306428/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
14

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTO..:

Gotlib, Jason ; Reiter, Andreas ; Radia, Deepti...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431238/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
15

Momelotinib long-term safety and survival in myelofibrosis:..:

Verstovsek, Srdan ; Mesa, Ruben ; Gupta, Vikas...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368854/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15